Assessment of myocardial salvage in patients with STEMI undergoing thrombolysis: ticagrelor versus clopidogrel

Table 3 CMR-derived measurements and Myocardial Salvage Index

CMR-derived measurements (5–6 month post-randomization)	Clopidogrel (n = 21)	Ticagrelor (n = 21)	p-value
Timing of CMR from Thrombolysis (Months)	5.66 ± 0.69	5.48 ± 0.59	0.38
EDVI (ml/m²)	69.28 ± 24.36	71.48 ± 13.69	0.72
ESVI (ml/m²)	34.83 ± 20.46	33.85 ± 11.66	0.85
SV (ml)	70.39 ± 18.99	79.71 ± 19.21	0.12
SVI (ml/m²)	35.28 (28.51–38.6)	39.04 (31.05–45.23)	0.079
LVEF (%)	51.94 ± 12.18	54.14 ± 10.37	0.53
Infarct total extent (% LV)	24.4 ± 15.66	26.65 ± 17.49	0.66
Maximal transmurality (%)	86.48 (89–100)	82.38 (71–100)	0.87
Mean transmurality (%)	48.1 ± 22.2	45.13 ± 20.66	0.65
Scar Volume (ml)	9.96 (4.84–26.97)	17.27 (4.02–24.14)	0.49
Final infarct Size (% LV)	10.7 ± 8.25	12.09 ± 8.72	0.6
MSI-BARI	52.25 ± 30.5	54.29 ± 31.08	0.83
MSI-APPROACH	51.94 ± 30.01	53.09 ± 32.39	0.9

Data are presented as mean ± Standard Deviation, median (quartiles 1–3), or number and percentage of patients. p-values express comparison between the two groups (Clopidogrel versus Ticagrelor)
CMR Cardiac magnetic resonance imaging, EDVI Left ventricular end-diastolic volume index, ESVI Left ventricular end-systolic volume index, SV Stroke volume, SVI Stroke volume index, LV Left ventricle, LVEF Left ventricular ejection fraction, MSI-BARI/APPROACH Myocardial Salvage Index calculated after estimation of Area At Risk with the use of the BARI/APPROACH angiographic scoring systems, % LV Percentage of left ventricular myocardium

ISSN: 1471-2261